Who is sponsoring NCT01073462?

NCT01073462 is sponsored by AbbVie (prior sponsor, Abbott).

What condition does NCT01073462 study?

NCT01073462 studies Secondary Hyperparathyroidism, Chronic Kidney Disease Stage V, Cardiac Morbidity.

What is the status of NCT01073462?

NCT01073462 is currently COMPLETED.

Last reviewed 2014-06-09 · How we verify

Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.

NCT01073462 COMPLETED Results posted

The purpose of this study was to ascertain the percentage of cardiac patients with chronic kidney disease (CKD) stage 5 treated with paricalcitol IV achieving intact parathyroid hormone (iPTH) levels in target range of Kidney Disease Outcomes Quality Initiative (K/DOQI) treatment guidelines (150 - 300 pg/mL) after 2 years.

Details

Lead sponsor	AbbVie (prior sponsor, Abbott)
Status	COMPLETED
Enrolment	67
Start date	2008-12
Completion	2013-06

Conditions

Secondary Hyperparathyroidism
Chronic Kidney Disease Stage V
Cardiac Morbidity

Primary outcomes

Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range — Baseline and Months 3, 6, 12, 18, and 24
Target range of intact parathyroid hormone was defined according to the Kidney Disease Outcomes Quality Initiative (K/DOQI) treatment guidelines as between 15.9 - 31.8 pmol/L (150 to 300 pg/mL).

Countries

Austria